MIR210HG may promote the progression of preeclampsia through CDHR5

Abstract Introduction:Because early diagnosis and timely detection of preeclampsia (PE) remains challenge. This study aims to explore the differential expression and pathogenic mechanism of the lncRNA MIR210HG in peripheral blood, which will lay the basis for its use as a biomarker of PE. Methods: Total RNA was extracted from the peripheral blood of 88 women with preeclamptic pregnancies and 81 women with normal pregnancies. The MIR210HG expression levels were determined by RT-PCR and western blot. SiRNA and MIR210HG overexpression plasmids were constructed and transfected into human trophoblast and vascular endothelial cells. Results: The lncRNA MIR210HG was significantly upregulated in the peripheral blood of patients with PE compared to the control group. Additionally, the expression level of MIR210HG in patients with early-onset PE was significantly higher than that of the control and late-onset PE groups. CDHR5, identified by bioinformatics predictions after RT-PCR confirmation, was upregulated in placental tissue compared to the control group. Furthermore, cytology experiments confirmed that knockdown of MIR210HG also decreased CDHR5 in human trophoblast and vascular endothelial cells. After knockdown of CDHR5, expression of MIR210HG was also reduced. Discussion: The lncRNA MIR210HG is highly expressed in the peripheral blood of PE, indicating MIR210HG may become a potential biomarker for the diagnosis and prediction of PE. In addition, MIR210HG may interact with CDHR5 to jointly promote the progression of PE. However, further experiments are needed to confirm the pathogenic mechanism.